We designed a study to characterize the expression of interferon alpha-2 (<i>IFNA2</i>) and interferon beta-1 (<i>IFNB1</i>), both type-1 interferons (IFN-1), interferon-gamma (<i>IFNG</i>), a type-2 interferon (IFN-2), ISGs, and NF-κB response genes in the upper respiratory tract (URT) of patients with mild (outpatient) versus severe (hospitalized) COVID-19. The gene discussed is IFNA2; the disease is COVID-19.